T14 Stock Overview Produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Tianjin Pharmaceutical Da Ren Tang Group Historical stock prices Current Share Price CN¥2.18 52 Week High CN¥2.66 52 Week Low CN¥1.66 Beta 0.80 1 Month Change -2.24% 3 Month Change 2.83% 1 Year Change 12.37% 3 Year Change 92.92% 5 Year Change 157.99% Change since IPO 389.54%
Recent News & Updates
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Wang Lei as General Manager Dec 10
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Election of Wang Lei as Chairman of the Board Nov 29
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Q3, 2024 Results on Oct 31, 2024 Sep 30 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) completed the acquisition of additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393). Aug 07
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2024 Results on Aug 15, 2024 Jun 28
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Final Dividend for the Year Ended December 31, 2023, Payable July 12, 2024 Jun 25 See more updates
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Wang Lei as General Manager Dec 10
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Election of Wang Lei as Chairman of the Board Nov 29
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Q3, 2024 Results on Oct 31, 2024 Sep 30 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) completed the acquisition of additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393). Aug 07
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2024 Results on Aug 15, 2024 Jun 28
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Final Dividend for the Year Ended December 31, 2023, Payable July 12, 2024 Jun 25
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes May 16
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Recommends Dividend Apr 30
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, Annual General Meeting, May 15, 2024 Mar 30
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Q1, 2024 Results on Apr 30, 2024 Mar 29
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Fiscal Year 2023 Results on Mar 30, 2024 Dec 29
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Board Changes Dec 19 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Zhu Haifeng as an Independent and Non-Executive Director
Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) A Risky Investment? Nov 03
Third quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.34 in 3Q 2022) Oct 31
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Mr. Zhu Haifeng as an Independent Director of the Company, as Well as Chairman of Remuneration Committee, and A Member of Each of Audit Committee, the Nomination Committee, and Strategy Committee Oct 14
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million. Sep 12
Is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Expensive For A Reason? A Look At Its Intrinsic Value Aug 08 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Ma Jian as Chief Financial Officer
Should You Be Adding Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) To Your Watchlist Today? Jul 21
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Half Year Ended 30 June 2023 Jul 15 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2023 Results on Aug 15, 2023 Jun 28
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Executive Changes Jun 22
We Think Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Can Manage Its Debt With Ease Jun 20
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Final Dividend for the Financial Period Ended 31 December 2022, Payable on or About 6 June 2023 May 20
If EPS Growth Is Important To You, Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Presents An Opportunity Apr 17
Investor sentiment improves as stock rises 23% Apr 07
Full year 2022 earnings released: EPS: CN¥1.12 (vs CN¥1.00 in FY 2021) Apr 01
Calculating The Intrinsic Value Of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Mar 01
Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Has A Pretty Healthy Balance Sheet Feb 03
High number of new directors Jan 05
Now 21% undervalued Jan 04 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Wong Gang as Independent and Non-Executive Director
High number of new directors Nov 16
Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.26 in 3Q 2021) Oct 30
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Zhang as Director Oct 28 Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Wang Lei as General Manager
Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.32 in 2Q 2021) Aug 15
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Final Dividend for the Financial Period Ended 31 December 2021, to Be Paid on or About 2 June 2022 May 18
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Appoints Zhang Yu as Chief Production Officer May 02
First quarter 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.28 in 1Q 2021) May 01
Less than half of directors are independent Apr 27
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, Annual General Meeting, May 16, 2022 Apr 01
Full year 2021 earnings released Apr 01
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Recommends to Declare Dividends for the Year Ended 31 December 2021 Mar 31
Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.20 in 3Q 2020) Oct 31
Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.20 in 2Q 2020) Aug 15
Investor sentiment improved over the past week Jul 21
Independent Non-Executive Director has left the company May 19
First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.22 in 1Q 2020) May 02 Tianjin Pharmacy Holdings Co., Ltd. completed the acquisition of 31.02% stake in Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (SGX:T14).
Full year 2020 earnings released Mar 31
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Cessation of Ni Zhenguo as Deputy General Manager Jan 31
Investor sentiment improved over the past week Dec 17
New 90-day high: US$0.90 Dec 12
New 90-day high: US$0.86 Nov 18
Third quarter earnings released Oct 31
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report Q3, 2020 Results on Oct 31, 2020 Oct 29
New 90-day low - US$0.79 Sep 14
Earnings released Aug 15
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Declares No Dividend Has for the Half Year Ended June 30, 2020 Aug 15
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report First Half, 2020 Results on Aug 15, 2020 Jul 06 Shareholder Returns T14 SG Pharmaceuticals SG Market 7D 1.4% -0.8% -2.1% 1Y 12.4% 9.2% 12.3%
See full shareholder returns
Return vs Market: T14 matched the SG Market which returned 12.3% over the past year.
Price Volatility Is T14's price volatile compared to industry and market? T14 volatility T14 Average Weekly Movement 5.1% Pharmaceuticals Industry Average Movement 6.2% Market Average Movement 4.5% 10% most volatile stocks in SG Market 13.5% 10% least volatile stocks in SG Market 1.9%
Stable Share Price: T14 has not had significant price volatility in the past 3 months compared to the SG market.
Volatility Over Time: T14's weekly volatility (5%) has been stable over the past year.
About the Company Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongjin Tablets, Qingfei Xiaoyan Pills, Huoxiangzhengqi Soft Capsules, Tongmai Yangxin Pills, Weichangan Pills, Qingyan Dropping Pills, Haima Bushen Pills, Angong Niuhuang Pills, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, etc. The company also engages in pharmaceutical commercial logistic services; pharmaceuticals retail; chemical raw materials and preparations; and biomedicine.
Show more Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamentals Summary How do Tianjin Pharmaceutical Da Ren Tang Group's earnings and revenue compare to its market cap? T14 fundamental statistics Market cap US$2.95b Earnings (TTM ) US$127.79m Revenue (TTM ) US$1.10b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) T14 income statement (TTM ) Revenue CN¥8.04b Cost of Revenue CN¥4.30b Gross Profit CN¥3.74b Other Expenses CN¥2.81b Earnings CN¥932.37m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.21 Gross Margin 46.50% Net Profit Margin 11.60% Debt/Equity Ratio 19.8%
How did T14 perform over the long term?
See historical performance and comparison Dividends
4.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 07:52 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Yalei Yan Bohai Securities Co., Ltd. Chengzhi Chen CGS International Shanshan Li China Merchants Securities Co. Ltd.
Show 6 more analysts 
